Oncology

#Drug development #Oncology #Podcast

Mini–library approach delivers an arsenal in drug development pipeline

This is the latest episode of the free DDW podcast, “Mini-library approach delivers an arsenal in drug development pipeline”. It covers a narrated article written for Volume 22, Issue 3 –Summer 2021 of DDW. In the article, Dr. Naganna Nimishetti, Chief of the Small Molecule Drug Discovery Division (SMDD) and… Read More

#News

#Drug development #Narrated podcasts #Oncology #Podcast

Mini-library approach delivers an arsenal in drug development pipeline

This is the latest episode of the free narrated DDW podcast, “Mini-library approach delivers an arsenal in drug development pipeline”. It covers a narrated article written for Volume 22, Issue 3 –Summer 2021 of DDW. In the article, Dr. Naganna Nimishetti, Chief of the Small Molecule Drug Discovery… Read More

#Podcasts

#Eli Lilly #MHRA #Oncology #Regulatory

MHRA approves Eli Lilly’s breast cancer oral inhibitor  

The Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorisation to Eli Lilly’s oral inhibitor abemaciclib for the treatment of patients with a specific type of breast cancer.   Abemaciclib will now be able to be used in combination with endocrine therapy for the adjuvant treatment… Read More

#News

#Cancer Research UK #Oncology #Stichting Oncode Institute

Cancer Research UK & Oncode to boost international collaboration  

Cancer Research UK has formed a strategic alliance with a research institute in the Netherlands as part of a joint effort to boost understanding into cancer and to translate research in patient benefits.   Cancer Research UK will work with the Stichting Oncode Institute in the Netherlands on… Read More

#News

#Cancer #Immunotherapy #Oncology

eBook: Insight into the latest oncology innovation

This 26-page DDW eBook, sponsored by The Jackson Laboratory, contains exclusive insight from industry experts on: How machine learning is currently used across different stages of cancer research Accelerating research: the path forward for treating rare cancers Immunotherapy challenges and the tools for research Why combination immunotherapies are one… Read More

#Cancer Research #News

#Collaboration #Immunology #Oncology

Amphista Therapeutics signs on drug development projects  

Amphista Therapeutics, a company focused on the development of next generation targeted protein degradation (TPD) therapeutics, has signed a strategic collaboration and license agreement with Bristol Myers Squibb.   The companies will work together to discover and develop small molecule protein degraders. Bristol Myers Squibb will be granted a global… Read More

#News

Human liver
#Biologics #Liver cancer #Oncology

AstraZeneca’s liver cancer therapy gets accepted for review  

AstraZeneca’s Biologics License Application (BLA) for tremelimumab has been accepted for Priority Review in the US, the company has announced. Tremelimumab is a human monoclonal antibody which AstraZeneca is investigating as a potential therapy for cancers. It works by targeting the activity of cytotoxic T-lymphocyte-associated protein 4 (CTLA-4). Now, tremelimumab… Read More

#News

#Biopharma #Clinical research #Oncology

Biomunex appoints CSO to drive oncology R&D  

Biopharma company Biomunex Pharmaceuticals has appointed a new chief scientific officer (CSO) to the company and member of its scientific advisory board.   The company has appointed Dr Simon Plyte as CSO who joins Biomunex to help strengthen its R&D strategy.   Dr Plyte brings a wealth… Read More

#News

#Cannabinoid #Oncology

Cannabotech targets US market with partnership 

Biomedical startup Cannabotech has partnered with the Californian corporation go NXT LVL in a move which will enable it to manufacture cannabidiol products in California.  Specifically, the agreement will allow Cannabotech’s integrative oncology products to be developed and manufactured at Go NXT LVL’s facilities… Read More

#News

#National Institute for Health and Care Excellence (NICE) #Oncology #Regulatory

Merck & Pfizer’s bladder cancer drug gets NICE approval  

The National Institute for Health and Care Excellence (NICE) has overturned a previous decision where it chose not to recommend the immunotherapy BAVENCIO (avelumab) for the treatment of bladder cancer.  The decision comes after avelumab’s developers, Merck KGaA and Pfizer, appealed the prior Final… Read More

#Cancer Research #News

Laboratory research
#Oncology #Pancreatic cancer

Redx collaborates with Garvan on cancer project  

Biotechnology company RedX is collaborating with the Garvan Institute of Medical Research on a project investigating novel therapeutic targets in cancer-associated fibrosis.  The collaboration aims to better understand treatments that could lead to increased patient survival in currently very poorly treated highly fibrotic cancers, such as… Read More

#Cancer Research #News

#Appointment #Business #Oncology

CellCentric appoints experienced oncology leaders  

Biotechnology company CellCentric has strengthened its leadership team with two new appointments. The company has appointed Kris Frese as Director of Cancer Biology, and Andrew Hughes, who joins the Board as a Non-Executive Director.   Kris Frese is an experienced cancer biologist who specialises in models of… Read More

#News

#Clinical trials #Events #Life sciences #Oncology #Rare disease

BioTrinity 2022: Catalysing growth in the life sciences industry 

BioTrinity 2022 will take place April 26-27, 2022 at 155 Bishopsgate in London, UK.   The BioTrinity conference aims to catalyse growth and supports in-person engagement across the life sciences industry. The event will be attended by early-stage and emerging life sciences R&D companies, investors, large pharma,… Read More

#News

#Biomedical research #Cancer #Cannabinoid #Oncology #Plant-based

Can cannabis and mushroom-based products eliminate colon cancer cells?

Cannabotech, a biomedical company developing oncological products based on cannabis and mushroom extracts, reports cell model study results showing that its ‘integrative-colon’ products killed over 90% of colon cancer cells. These products are based on a combination of several cannabinoids from the cannabis plant and various mushroom extracts. The study… Read More

#Cancer Research #Editor's Choice #News #Trending News

#Cancer research #Immunotherapy #Oncology #Tumours

Immunotherapy challenges and tools for research 

Sonia Marsilio is an Associate Product Manager at Enzo. She explains how research tools enable scientists to accelerate immunotherapy.  The growing, continuously evolving arsenal of cancer immunotherapies has changed the treatment landscape of many tumours. Dominating the space are the CAR T cell therapies, with CD19, BCMA, and CD22… Read More

#Cancer Research #Editor's Choice #News #Opinion